NO20006645L - Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme - Google Patents

Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme

Info

Publication number
NO20006645L
NO20006645L NO20006645A NO20006645A NO20006645L NO 20006645 L NO20006645 L NO 20006645L NO 20006645 A NO20006645 A NO 20006645A NO 20006645 A NO20006645 A NO 20006645A NO 20006645 L NO20006645 L NO 20006645L
Authority
NO
Norway
Prior art keywords
irbesartan
obtaining
same
pharmaceutical preparations
preparations containing
Prior art date
Application number
NO20006645A
Other languages
English (en)
Other versions
NO20006645D0 (no
NO317786B1 (no
Inventor
Bruno Franc
Christian Hoff
Sam Kiang
Mark D Lindrud
Olivier Monnier
Chenkou Wei
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9527829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20006645(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NO20006645D0 publication Critical patent/NO20006645D0/no
Publication of NO20006645L publication Critical patent/NO20006645L/no
Publication of NO317786B1 publication Critical patent/NO317786B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NO20006645A 1998-06-24 2000-12-22 Ny form av irbesartan, fremgangsmate for a oppna den nevnte form og farmasoytiske preparater inneholdende den samme NO317786B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9808037A FR2780403B3 (fr) 1998-06-24 1998-06-24 Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
PCT/FR1999/001372 WO1999067236A1 (fr) 1998-06-24 1999-06-10 Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant

Publications (3)

Publication Number Publication Date
NO20006645D0 NO20006645D0 (no) 2000-12-22
NO20006645L true NO20006645L (no) 2001-02-26
NO317786B1 NO317786B1 (no) 2004-12-13

Family

ID=9527829

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006645A NO317786B1 (no) 1998-06-24 2000-12-22 Ny form av irbesartan, fremgangsmate for a oppna den nevnte form og farmasoytiske preparater inneholdende den samme

Country Status (25)

Country Link
US (2) US6800761B1 (no)
EP (1) EP1089994B9 (no)
JP (1) JP2002518495A (no)
KR (1) KR20010034917A (no)
CN (1) CN1127499C (no)
AT (1) ATE275562T1 (no)
AU (1) AU747887B2 (no)
BG (1) BG105069A (no)
BR (1) BR9912198A (no)
CA (1) CA2335545A1 (no)
CZ (1) CZ292868B6 (no)
DE (1) DE69920017T2 (no)
EA (1) EA003410B1 (no)
FR (1) FR2780403B3 (no)
HU (1) HUP0103913A3 (no)
ID (1) ID27377A (no)
IL (1) IL140419A0 (no)
NO (1) NO317786B1 (no)
NZ (1) NZ508842A (no)
PL (1) PL345215A1 (no)
SK (1) SK20032000A3 (no)
TR (1) TR200003842T2 (no)
UA (1) UA55540C2 (no)
WO (1) WO1999067236A1 (no)
ZA (1) ZA200007588B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002346694A1 (en) * 2001-12-10 2003-06-23 Dr. Reddy's Laboratories Ltd. Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one
PT1509517E (pt) * 2003-01-16 2008-08-05 Teva Pharma Nova síntese de irbesartan
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AU2007202693B2 (en) * 2003-01-20 2009-12-10 Novartis Ag Process for modifying drug crystal formation
DE602004015071D1 (de) * 2003-02-05 2008-08-28 Teva Pharma Synthese von 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro-4,4 -nonen-4-on
MXPA06002145A (es) * 2003-08-27 2006-04-27 Boehringer Ingelheim Int Compuestos de cicloalquilaminoacidos, procedimiento para su elaboracion y sus usos.
WO2005113518A1 (en) * 2004-05-20 2005-12-01 Dr. Reddy's Laboratories Ltd. Process for preparing irbesartan
JP4880591B2 (ja) * 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
SI21848A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava seskvihidratne hidrokloridne soli tetrazolskega derivata
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
TWI346108B (en) 2004-08-23 2011-08-01 Bristol Myers Squibb Co A method for preparing irbesartan and intermediates thereof
GB2419592A (en) 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
US20090208573A1 (en) * 2004-11-11 2009-08-20 Lek Pharmaceuticals D.D Novel polymorph form of irbesartan
EP1806130B1 (en) 2006-01-09 2010-03-31 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising irbesartan
WO2008041957A1 (en) * 2006-10-03 2008-04-10 Ulkar Kimya Sanayi Ve Ticaret As Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
CA2682929A1 (en) * 2007-04-17 2008-10-23 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
NZ600110A (en) * 2007-09-10 2013-03-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt
ES2349317T3 (es) * 2007-11-28 2010-12-29 Laboratorios Lesvi, S.L. Formulaciones farmacéuticas que contienen irbesartán.
US20100234614A1 (en) * 2007-12-07 2010-09-16 Hetero Drugs Limited Process for pure irbesartan
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CZ302407B6 (cs) * 2009-03-12 2011-05-04 Univerzita Pardubice Zpusob prípravy 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-onu
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8772512B2 (en) * 2009-07-10 2014-07-08 Janssen Pharmaceutica Nv Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
PH12012500698A1 (en) * 2009-10-14 2016-05-27 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
ES2596291T3 (es) 2010-05-11 2017-01-05 Janssen Pharmaceutica, N.V. Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
CN103596944B (zh) 2011-04-13 2017-02-22 詹森药业有限公司 可用作sglt2的抑制剂的化合物的制备方法
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
LT3394051T (lt) * 2015-12-21 2020-08-10 Janssen Pharmaceutica N.V. Kristalizacijos procedūra, skirta kanagliflozino hemihidrato kristalų gavimui

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201738B (no) * 1990-03-20 1993-03-11 Sanofi Co
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Also Published As

Publication number Publication date
ID27377A (id) 2001-04-05
AU4048499A (en) 2000-01-10
DE69920017D1 (de) 2004-10-14
CZ292868B6 (cs) 2003-12-17
FR2780403B3 (fr) 2000-07-21
EP1089994B9 (fr) 2008-08-27
KR20010034917A (ko) 2001-04-25
EA003410B1 (ru) 2003-04-24
EP1089994B1 (fr) 2004-09-08
CA2335545A1 (en) 1999-12-29
EP1089994A1 (fr) 2001-04-11
HUP0103913A2 (hu) 2002-03-28
IL140419A0 (en) 2002-02-10
US20050032862A1 (en) 2005-02-10
EA200001221A1 (ru) 2001-08-27
BR9912198A (pt) 2001-04-10
FR2780403A1 (fr) 1999-12-31
NO20006645D0 (no) 2000-12-22
ZA200007588B (en) 2001-06-11
NZ508842A (en) 2002-09-27
ATE275562T1 (de) 2004-09-15
CN1306529A (zh) 2001-08-01
AU747887B2 (en) 2002-05-30
SK20032000A3 (sk) 2001-05-10
NO317786B1 (no) 2004-12-13
US6800761B1 (en) 2004-10-05
JP2002518495A (ja) 2002-06-25
BG105069A (en) 2001-11-30
UA55540C2 (uk) 2003-04-15
HUP0103913A3 (en) 2003-01-28
CZ20004771A3 (en) 2001-06-13
WO1999067236A1 (fr) 1999-12-29
TR200003842T2 (tr) 2001-06-21
PL345215A1 (en) 2001-12-03
DE69920017T2 (de) 2005-09-22
US7008959B2 (en) 2006-03-07
CN1127499C (zh) 2003-11-12

Similar Documents

Publication Publication Date Title
NO20006645L (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
NO991732L (no) Nye heterocyklylmetylsubstituerte pyrazolderivater
NO992400L (no) Nye substituerte pyrazolderivater
DK1200418T3 (da) Nematodicide trifluorbutener
PT915898E (pt) Forma i cristalina de claritromicina
DE60022230D1 (de) Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
MXPA03001463A (es) Derivados de benzofurano o benzotiofeno de aminoalquilbenzoil, metodo para preparar los mismos y composiciones que los contienen.
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
PL336640A1 (en) Substituted 3,3-diamino-2- propenonitriles, their production and application
MXPA03001536A (es) (aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen.
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
IL129616A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
ATE229519T1 (de) Neue cis-3,4-chromanderivate zur vorbeugung oder behandlung von oestrogenbezogenen krankheiten oder syndromen
DE69926223D1 (de) Verfahren zur herstellung von zwischenprodukten
DE69718500D1 (de) (-)-enantiomere von cis-3,4-chromanderivaten zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
ATE421961T1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
NO20031137D0 (no) Fremgangsmåte for fremstilling av kirale forbindelser
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
BG107553A (en) Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, methods for preparing same and compositions containing same
MEP56208A (en) Caloporoside derivatives, methods for the production thereof and their use
BG104964A (bg) Подобрен метод за получаване на фармацевтично ценни норбензоморфанови производни

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees